For AD, it is proposed to shift from a phenotype-based classification of neurodegenerative diseases to a molecular biomarker-based framework, encapsulated in the AT(N) system, which identifies the presence of amyloid (A), tau (T), and neurodegeneration (N) [58]. Here, MAPT is linked to Alzheimer disease.